Loading...
•
Jun 27
Danaher Q2 2025 Earnings Report
Danaher reported solid Q2 2025 results with revenue and adjusted EPS exceeding expectations.
Key Takeaways
Danaher posted strong Q2 2025 results driven by Bioprocessing growth and disciplined cost management, despite a fluid macro environment.
Revenue grew to $5.9 billion, up 3.5% year-over-year.
Adjusted EPS reached $1.80, exceeding expectations.
Net income came in at $555 million.
Strong Bioprocessing business contributed to solid performance.
Danaher
Danaher
Danaher Revenue by Segment
Revenue by Segment
Biotechnology Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comDiagnostics Revenue
CapyFin.com Forward Guidance
Danaher expects low-single digit core revenue growth for Q3 2025 and reaffirmed approximately 3% core revenue growth for the full year, with higher adjusted EPS guidance.
Positive Outlook
- Raised full-year adjusted EPS guidance to $7.70–$7.80.
- Low-single digit core revenue growth expected for Q3 2025.
- Full-year core revenue growth guidance maintained at ~3%.
- Bioprocessing momentum expected to continue.
- Strong cost management expected to support profitability.
Challenges Ahead
- Macro environment remains fluid.
- Life Sciences segment experiencing core sales decline.
- Diagnostics growth remains modest at 2%.
- Currency exchange rates impacting revenue growth.
- Ongoing uncertainty in global economic conditions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income